The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease

European Journal of Pharmacology

Volumn 490, Issue 1-3, 2004, Pages 127-133

  Carro, Eva ^a   Torres Aleman, Ignacio ^a  

^a INSTITUTO CAJAL   (Spain)

Author keywords

Alzheimer's disease; Blood brain barrier; Insulin; Insulin like growth factor I; Tau; Amyloid

Indexed keywords

AMYLOID BETA PROTEIN; HORMONE; INSULIN; SOMATOMEDIN C;

ALZHEIMER DISEASE; AMYLOIDOSIS; ATROPHY; BLOOD BRAIN BARRIER; BRAIN; BRAIN NERVE CELL; CELL ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MECHANISM; DRUG POTENCY; HORMONE ACTION; HORMONE STRUCTURE; HUMAN; INSULIN RESISTANCE; MOLECULAR MECHANICS; NERVE CELL; NERVE CELL NECROSIS; NEUROFILAMENT; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PATIENT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; REGULATORY MECHANISM; REVIEW; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; STIMULATION; STRUCTURE ANALYSIS;

EID: 1842633868     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.02.050     Document Type: Article

References (68)

1. Aguirre V., Werner E.D., Giraud J., Lee Y.H., Shoelson S.E., White M.F. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J. Biol. Chem. 277:2002;1531-1537.
2. Aleman A., Verhaar H.J., de Haan E.H., de Vries W.R., Samson M.M., Drent M.L., van der Veen E.A., Koppeschaar H.P. Insulin-like growth factor-I and cognitive function in healthy older men. J. Clin. Endocrinol. Metab. 84:1999;471-475.
3. Blair L.A., Marshall J. IGF-1 modulates N and L calcium channels in a PI 3-kinase-dependent manner. Neuron. 19:1997;421-429.
4. Blum-Degen D., Frolich L., Hoyer S., Riederer P. Altered regulation of brain glucose metabolism as a cause of neurodegenerative disorders? J. Neural Transm. (Suppl. 46):1995;139-147.
5. Bondy C.A., Cheng C.M. Insulin-like growth factor-1 promotes neuronal glucose utilization during brain development and repair processes. Int. Rev. Neurobiol. 51:2002;189-217.
6. Breese C.R., Ingram R.L., Sonntag W.E. Influence of age and long-term dietary restriction on plasma insulin-like growth factor-1 (IGF-1), IGF-1 gene expression, and IGF-1 binding proteins. J. Gerontol. 46:1991;B180-B187.
7. Bruunsgaard H., Andersen-Ranberg K., Jeune B., Pedersen A.N., Skinhoj P., Pedersen B.K. A high plasma concentration of TNF-alpha is associated with dementia in centenarians. J. Gerontol., Ser. A, Biol. Sci. Med. Sci. 54:1999;M357-M364.
8. Busiguina S., Fernandez A.M., Barrios V., Clark R., Tolbert D.L., Berciano J., Torres-Aleman I. Neurodegeneration is associated to changes in serum insulin-like growth factors. Neurobiol. Dis. 7:2000;657-665.
9. Carro E.M.et al. Insulin-like growth factor I and Alzheimer's disease: therapeutic prospects? Exp. Rev. Neurother. 4:2003;79-86.
10. Carro E., Nunez A., Busiguina S., Torres-Aleman I. Circulating insulin-like growth factor I mediates effects of exercise on the brain. J. Neurosci. 20:2000;2926-2933.
11. Carro E., Trejo J.L., Gomez-Isla T., LeRoith D., Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat. Med. 8:2002;1390-1397.
12. Castro-Alamancos M.A., Torres-Aleman I. Long-term depression of glutamate-induced gamma-aminobutyric acid release in cerebellum by insulin-like growth factor I. Proc. Natl. Acad. Sci. U. S. A. 90:1993;7386-7390.
13. Clark C.M., Karlawish J.H. Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. Ann. Intern. Med. 138:2003;400-410.
14. Craft S., Peskind E., Schwartz M.W., Schellenberg G.D., Raskind M., Porte D. Jr. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology. 50:1998;164-168.
15. Craft S., Asthana S., Schellenberg G., Cherrier M., Baker L.D., Newcomer J., Plymate S., LaTendresse S., Petrova A., Raskind M., Peskind E., Lofgreen C., Grimwood K. Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender. Neuroendocrinology. 70:1999;146-152.
16. Craft S., Asthana S., Schellenberg G., Baker L., Cherrier M., Boyt A.A., Martins R.N., Raskind M., Peskind E., Plymate S. Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype. Ann. N. Y. Acad. Sci. 903:2000;222-228.
17. de Pablo F., de la Rosa E.J. The developing CNS: a scenario for the action of proinsulin, insulin and insulin-like growth factors. Trends Neurosci. 18:1995;143-150.
18. Engelhardt B., Wolburg-Buchholz K., Wolburg H. Involvement of the choroid plexus in central nervous system inflammation. Microsc. Res. Tech. 52:2001;112-129.
19. Fadool D.A., Tucker K., Phillips J.J., Simmen J.A. Brain insulin receptor causes activity-dependent current suppression in the olfactory bulb through multiple phosphorylation of Kv1.3. J. Neurophysiol. 83:2000;2332-2348.
20. Farris W., Mansourian S., Chang Y., Lindsley L., Eckman E.A., Frosch M.P., Eckman C.B., Tanzi R.E., Selkoe D.J., Guenette S. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U. S. A. 100:2003;4162-4167.
21. Federici M., Giaccari A., Hribal M.L., Giovannone B., Lauro D., Morviducci L., Pastore L., Tamburrano G., Lauro R., Sesti G. Evidence for glucose/hexosamine in vivo regulation of insulin/IGF-I hybrid receptor assembly. Diabetes. 48:1999;2277-2285.
22. Fernandez A.M., Kim J.K., Yakar S., Dupont J., Hernandez-Sanchez C., Castle A.L., Filmore J., Shulman G.I., Le Roith D. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev. 15:2001;1926-1934.
23. Gasparini L., Xu H. Potential roles of insulin and IGF-1 in Alzheimer's disease. Trends Neurosci. 26:2003;404-406.
24. Gasparini L., Gouras G.K., Wang R., Gross R.S., Beal M.F., Greengard P., Xu H. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J. Neurosci. 21:2001;2561-2570.
25. Gasparini L., Netzer W.J., Greengard P., Xu H. Does insulin dysfunction play a role in Alzheimer's disease? Trends Pharmacol. Sci. 23:2002;288-293.
26. Golden P.L., Maccagnan T.J., Pardridge W.M. Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels. J. Clin. Invest. 99:1997;14-18.
27. Gonzalez D.L.V., Buno W., Pons S., Garcia-Calderat M.S., Garcia-Galloway E., Torres-Aleman I. Insulin-like growth factor I potentiates kainate receptors through a phosphatidylinositol 3-kinase dependent pathway. NeuroReport. 12:2001;1293-1296.
28. Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., Binder L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U. S. A. 83:1986;4913-4917.
29. Gutierrez-Ospina G., Saum L., Calikoglu A.S., Diaz-Cintra S., Barrios F.A., D'Ercole A.J. Increased neural activity in transgenic mice with brain IGF-I overexpression: a [3H]2DG study. NeuroReport. 8:1997;2907-2911.
30. Hanger D.P., Hughes K., Woodgett J.R., Brion J.P., Anderton B.H. Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci. Lett. 147:1992;58-62.
31. Jain S., Golde D.W., Bailey R., Geffner M.E. Insulin-like growth factor-I resistance. Endocr. Rev. 19:1998;625-646.
32. Kamenetz F., Tomita T., Hsieh H., Seabrook G., Borchelt D., Iwatsubo T., Sisodia S., Malinow R. APP processing and synaptic function. Neuron. 37:2003;925-937.
33. Kanzaki M., Zhang Y.Q., Mashima H., Li L., Shibata H., Kojima I. Translocation of a calcium-permeable cation channel induced by insulin-like growth factor-I. Nat. Cell Biol. 1:1999;165-170.
34. Lang C.H., Vary T.C., Frost R.A. Acute in vivo elevation of insulin-like growth factor (IGF) binding protein-1 decreases plasma free IGF-I and muscle protein synthesis. Endocrinology. 144:2003;3922-3933.
35. Lee W.H., Michels K.M., Bondy C.A. Localization of insulin-like growth factor binding protein-2 messenger RNA during postnatal brain development: correlation with insulin-like growth factors I and II. Neuroscience. 53:1993;251-265.
36. Ling X., Martins R.N., Racchi M., Craft S., Helmerhorst E. Amyloid beta antagonizes insulin promoted secretion of the amyloid beta protein precursor. J. Alzheimer's Dis. 4:2002;369-374.
37. Liou J.C., Tsai F.Z., Ho S.Y. Potentiation of quantal secretion by insulin-like growth factor-1 at developing motoneurons in Xenopus cell culture. J. Physiol. 553:2003;719-728.
38. Man Y.H., Lin J.W., Ju W.H., Ahmadian G., Liu L., Becker L.E., Sheng M., Wang Y.T. Regulation of AMPA receptor-mediated synaptic transmission by clathrin-dependent receptor internalization. Neuron. 25:2000;649-662.
39. Mattson M.P. Brain evolution and lifespan regulation: conservation of signal transduction pathways that regulate energy metabolism. Mech. Ageing Dev. 123:2002;947-953.
40. Miklossy J., Kraftsik R., Pillevuit O., Lepori D., Genton C., Bosman F.T. Curly fiber and tangle-like inclusions in the ependyma and choroid plexus - a pathogenetic relationship with the cortical Alzheimer-type changes? J. Neuropathol. Exp. Neurol. 57:1998;1202-1212.
41. Moran A., Jacobs D.R. Jr., Steinberger J., Cohen P., Hong C.P., Prineas R., Sinaiko A.R. Association between the insulin resistance of puberty and the insulin-like growth factor-I/growth hormone axis. J. Clin. Endocrinol. Metab. 87:2002;4817-4820.
42. Mustafa A., Lannfelt L., Lilius L., Islam A., Winblad B., Adem A. Decreased plasma insulin-like growth factor-I level in familial Alzheimer's disease patients carrying the Swedish APP 670/671 mutation. Dement. Geriatr. Cogn. Disord. 10:1999;446-451.
43. Nunez A., Carro E., Torres-Aleman I. Insulin-like growth factor I modifies electrophysiological properties of brainstem neurons. J. Neurophysiol. 89:2003;3008-3017.
44. O'Connell T., Clemmons D.R. IGF-I/IGF-binding protein-3 combination improves insulin resistance by GH-dependent and independent mechanisms. J. Clin. Endocrinol. Metab. 87:2002;4356-4360.
45. Petty M.A., Lo E.H. Junctional complexes of the blood-brain barrier: permeability changes in neuroinflammation. Prog. Neurobiol. 68:2002;311-323.
46. Phiel C.J., Wilson C.A., Lee V.M., Klein P.S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature. 423:2003;435-439.
47. Remarque E.J., Bollen E.L., Weverling-Rijnsburger A.W., Laterveer J.C., Blauw G.J., Westendorp R.G. Patients with Alzheimer's disease display a pro-inflammatory phenotype. Prog. Neurobiol. 36:2001;171-176.
48. Riddle D.R., Sonntag W.E., Lichtenwalner R.J. Microvascular plasticity in aging. Ageing Res. Rev. 2:2003;149-168.
49. Rui L., Aguirre V., Kim J.K., Shulman G.I., Lee A., Corbould A., Dunaif A., White M.F. Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J. Clin. Invest. 107:2001;181-189.
50. Sakai K., Lowman H.B., Clemmons D.R. Increases in free, unbound insulin-like growth factor I enhance insulin responsiveness in human hepatoma G2 cells in culture. J. Biol. Chem. 277:2002;13620-13627.
51. Sandhu M.S., Heald A.H., Gibson J.M., Cruickshank J.K., Dunger D.B., Wareham N.J. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet. 359:2002;1740-1745.
52. Schubert M., Brazil D.P., Burks D.J., Kushner J.A., Ye J., Flint C.L., Farhang-Fallah J., Dikkes P., Warot X.M., Rio C., Corfas G., White M.F. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J. Neurosci. 23:2003;7084-7092.
53. Schwartz M.W., Figlewicz D.P., Baskin D.G., Woods S.C., Porte D. Jr. Insulin in the brain: a hormonal regulator of energy balance. Endocr. Rev. 13:1992;387-414.
54. Selkoe D.J. Clearing the brain's amyloid cobwebs. Neuron. 32:2001;177-180.
55. Serot J.M., Christmann D., Dubost T., Couturier M. Cerebrospinal fluid transthyretin: aging and late onset Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry. 63:1997;506-508.
56. Solerte S.B., Cravello L., Ferrari E., Fioravanti M. Overproduction of IFN-gamma and TNF-alpha from natural killer (NK) cells is associated with abnormal NK reactivity and cognitive derangement in Alzheimer's disease. Ann. N. Y. Acad. Sci. 917:2000;331-340.
57. Strazielle N., Ghersi-Egea J.F. Choroid plexus in the central nervous system: biology and physiopathology. J. Neuropathol. Exp. Neurol. 59:2000;561-574.
58. Tham A., Nordberg A., Grissom F.E., Carlsson-Skwirut C., Viitanen M., Sara V.R. Insulin-like growth factors and insulin-like growth factor binding proteins in cerebrospinal fluid and serum of patients with dementia of the Alzheimer type. J. Neural Transm., Parkinson's Dis. Dement. Sect. 5:1993;165-176.
59. Trejo J.L., Carro E., Garcia-Galloway E., Torres-Aleman I. Role of insulin-like growth factor I signaling in neurodegenerative diseases. J. Mol. Med. 82:2003;156-162.
60. Walker L.C., Pahnke J., Madauss M., Vogelgesang S., Pahnke A., Herbst E.W., Stausske D., Walther R., Kessler C., Warzok R.W. Apolipoprotein E4 promotes the early deposition of Abeta42 and then Abeta40 in the elderly. Acta Neuropathol. (Berl.). 100:2000;36-42.
61. Wan Q., Xiong Z.G., Man H.Y., Ackerley C.A., Braunton J., Lu W.Y., Becker L.E., MacDonald J.F., Wang Y.T. Recruitment of functional GABA(A) receptors to postsynaptic domains by insulin. Nature. 388:1997;686-690.
62. Watson G.S., Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs. 17:2003;27-45.
63. Watson G.S., Peskind E.R., Asthana S., Purganan K., Wait C., Chapman D., Schwartz M.W., Plymate S., Craft S. Insulin increases CSF Abeta42 levels in normal older adults. Neurology. 60:2003;1899-1903.
64. Weller R.O., Yow H.Y., Preston S.D., Mazanti I., Nicoll J.A. Cerebrovascular disease is a major factor in the failure of elimination of Abeta from the aging human brain: implications for therapy of Alzheimer's disease. Ann. N. Y. Acad. Sci. 977:2002;162-168.
65. Wilczak N., de Vos R.A., De Keyser J. Free insulin-like growth factor (IGF)-I and IGF binding proteins 2, 5, and 6 in spinal motor neurons in amyotrophic lateral sclerosis. Lancet. 361:2003;1007-1011.
66. Willis P.E., Chadan S., Baracos V., Parkhouse W.S. Acute exercise attenuates age-associated resistance to insulin-like growth factor I. Am. J. Physiol. 272:1997;E397-E404.
67. Xie L., Helmerhorst E., Taddei K., Plewright B., Van Bronswijk W., Martins R. Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. J. Neurosci. 22:2002;RC221.
68. Yakar S., Liu J.L., Fernandez A.M., Wu Y., Schally A.V., Frystyk J., Chernausek S.D., Mejia W., Le Roith D. Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes. 50:2001;1110-1118.